Literature DB >> 33215878

Impact of chronic intermittent hypoxia on the long non-coding RNA and mRNA expression profiles in myocardial infarction.

Chaowei Hu1, Jing Li2, Yunhui Du1, Juan Li1,3, Yunyun Yang1,3, Yifan Jia4, Lu Peng1, Yanwen Qin1,3, Yongxiang Wei1,5.   

Abstract

Chronic intermittent hypoxia (CIH) is the primary feature of obstructive sleep apnoea (OSA), a crucial risk factor for cardiovascular diseases. Long non-coding RNAs (lncRNAs) in myocardial infarction (MI) pathogenesis have drawn considerable attention. However, whether CIH participates in the modulation of lncRNA profiles during MI is yet unclear. To investigate the influence of CIH on MI, cardiac damage was assessed by histology and echocardiography, and lncRNA and mRNA integrated microarrays were screened. MI mouse model showed myocardial hypertrophy, aggravated inflammation and fibrosis, and compromised left ventricle function under CIH. Compared with normoxia, 644 lncRNAs and 1084 differentially expressed mRNAs were identified following CIH for 4 weeks, whereas 1482 lncRNAs and 990 mRNAs were altered at 8 weeks. Strikingly, reoxygenation after CIH markedly affected 1759 lncRNAs and 778 mRNAs. Of these, 11 lncRNAs modulated by CIH were restored after reoxygenation and were validated by qPCR. The GO terms and KEGG pathways of genes varied significantly by CIH. lncRNA-mRNA correlation further showed that lncRNAs, NONMMUT032513 and NONMMUT074571 were positively correlated with ZEB1 and negatively correlated with Cmbl. The current results demonstrated a causal correlation between CIH and lncRNA alternations during MI, suggesting that lncRNAs might be responsible for MI aggravation under CIH.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic intermittent hypoxia; lncRNA; mRNA; myocardial infarction

Year:  2020        PMID: 33215878      PMCID: PMC7810970          DOI: 10.1111/jcmm.16097

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  58 in total

1.  Endoplasmic reticulum stress as a novel inducer of hypoxia inducible factor-1 activity: its role in the susceptibility to myocardial ischemia-reperfusion induced by chronic intermittent hypoxia.

Authors:  Elise Belaidi; Amandine Thomas; Guillaume Bourdier; Sophie Moulin; Emeline Lemarié; Patrick Levy; Jean-Louis Pépin; Irina Korichneva; Diane Godin-Ribuot; Claire Arnaud
Journal:  Int J Cardiol       Date:  2016-02-17       Impact factor: 4.164

2.  miRNA-Mediated Suppression of a Cardioprotective Cardiokine as a Novel Mechanism Exacerbating Post-MI Remodeling by Sleep Breathing Disorders.

Authors:  Yunhui Du; Xiao Wang; Linyi Li; Wenjing Hao; Huina Zhang; Yu Li; Yanwen Qin; Shaoping Nie; Theodore A Christopher; Bernard L Lopez; Wayne Bond Lau; Yajing Wang; Xin-Liang Ma; Yongxiang Wei
Journal:  Circ Res       Date:  2019-11-07       Impact factor: 17.367

3.  Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.

Authors:  Meilin Ma; Haixia Xu; Geng Liu; Jing Wu; Chunhua Li; Xiuxuan Wang; Sifan Zhang; Heng Xu; Shenggen Ju; Wei Cheng; Lunzhi Dai; Yuquan Wei; Yan Tian; Xianghui Fu
Journal:  Hepatology       Date:  2019-04-26       Impact factor: 17.425

4.  Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea.

Authors:  Elise Belaidi; Marie Joyeux-Faure; Christophe Ribuot; Sandrine H Launois; Patrick Levy; Diane Godin-Ribuot
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

5.  Functional polymorphism of lncRNA MALAT1 contributes to pulmonary arterial hypertension susceptibility in Chinese people.

Authors:  Yufeng Zhuo; Qingchun Zeng; Peng Zhang; Guoyang Li; Qiang Xie; Ying Cheng
Journal:  Clin Chem Lab Med       Date:  2017-01-01       Impact factor: 3.694

6.  Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats.

Authors:  Bingong Li; Zeqi Zheng; Yunfeng Wei; Menghong Wang; Jingtian Peng; Ting Kang; Xin Huang; Jian Xiao; Yong Li; Zhe Li
Journal:  Cardiovasc Diabetol       Date:  2011-07-29       Impact factor: 9.951

7.  The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells.

Authors:  Hsin-Chen Lin; Ching-Ching Yeh; Lo-Yun Chao; Mong-Hsun Tsai; Hung-Hsin Chen; Eric Y Chuang; Liang-Chuan Lai
Journal:  Oncotarget       Date:  2017-12-28

8.  Exosomal lncRNA GAS5 regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis.

Authors:  Lei Chen; Wenjin Yang; Yijun Guo; Wei Chen; Ping Zheng; Jinsong Zeng; Wusong Tong
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

9.  Circulating Long Noncoding RNA UCA1 as a Novel Biomarker of Acute Myocardial Infarction.

Authors:  Youyou Yan; Bin Zhang; Ning Liu; Chao Qi; Yanlong Xiao; Xin Tian; Tianyi Li; Bin Liu
Journal:  Biomed Res Int       Date:  2016-02-01       Impact factor: 3.411

10.  ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.

Authors:  D H Peng; C Ungewiss; P Tong; L A Byers; J Wang; J R Canales; P A Villalobos; N Uraoka; B Mino; C Behrens; I I Wistuba; R I Han; C A Wanna; M Fahrenholtz; K J Grande-Allen; C J Creighton; D L Gibbons
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

View more
  2 in total

1.  Knockdown of LncRNA NEAT1 inhibits myofibroblast activity in oral submucous fibrosis through miR-760/TPM1 axis.

Authors:  Wei Li; Bin Cheng
Journal:  J Dent Sci       Date:  2021-12-08       Impact factor: 3.719

2.  Impact of chronic intermittent hypoxia on the long non-coding RNA and mRNA expression profiles in myocardial infarction.

Authors:  Chaowei Hu; Jing Li; Yunhui Du; Juan Li; Yunyun Yang; Yifan Jia; Lu Peng; Yanwen Qin; Yongxiang Wei
Journal:  J Cell Mol Med       Date:  2020-11-20       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.